Home
Vertex and CRISPR Complete Submission of BLAs to the US FDA for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

Vertex and CRISPR Complete Submission of BLAs to the US FDA for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

Today’s Highlights April 3, 2023

Vertex Pharmaceuticals and CRISPR Therapeutics Completion of BLAs
Vertex Pharmaceuticals (VRTX) and CRISPR Therapeutics (CRSP) announced the completion of the . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.
Today’s Highlights
,
April 3, 2023

Other Articles